Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorGuo Xufeng
About this trial
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved survival outcomes.
Eligibility criteria
Qualifiers
The patient volunteers to participate in the study, signs a consent form, has good compliance, and obeys the follow-up, and is willing and able to follow the protocol during the study;
Histologically-confirmed squamous cell carcinoma; tumors of the esophagus are located in the thoracic cavity;
Have not received systemic and local treatment for esophageal cancer;
Pre-treatment staging as cT1b-3N1-3M0 or T3N0M0, American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) 8th edition;
Disqualifiers
Unresectable factors, including those who are unresectable for tumor reasons or have surgical contraindications, or who refuse surgery;
Patients with supraclavicular lymph node metastasis;
Poor nutritional status, BMI<18.5Kg/m2; Patients could continue to be considered for enrollment if corrected with symptomatic nutritional support before enrollment and after assessment by the principal investigator
Allergy to any drugs;
Trial design
Treatments tested in this trial
- Tislelizumab
Treatment groups
73 Participants
are divided into 1 treatment groupSponsors and collaborators
Guo Xufeng
Lead sponsor
Shanghai Chest Hospital
Sponsor institution
Source ClinicalTrials.gov